“Although meningioma patients often see positive tumor results, many tumors still recur after surgery.”
BUFFALO, NY – January 17, 2023 – A new research paper has been published in Oncology (Volume 9) on December 9, 2022, entitled “Association between tumor mutations and meningioma recurrence in grade I/II disease. “
Meningiomas are common intracranial tumors with a variable prognosis that is not fully captured by commonly used classification schemes. In this new study, researchers Jonathan T. Cibra, Melissa Amphlett, And Raj K. Shrivastava from Icahn School of Medicine at Mount Sinai And Sima 4 (The Mount Sinai Project) sought to determine the association between meningioma mutations and neoplastic outcomes using a targeted next-generation sequencing panel.
“As such, further characterization of the mechanisms of meningioma disease is needed in the pursuit of better prognosis and new targets for improved treatment models.”
The team identified 184 grade I and II meningiomas with more than 90 days of follow-up after surgery and linked targeted next-generation sequencing. For transgenes in more than 5% of the sample, Cox regression models for progression-free survival were calculated stratified by gene. They then built a multigene model by including all gene predictions with a s-value less than 0.20. Starting with this model, the researchers performed a retrospective selection to identify the most predictive factors.
ATM (HR = 4.448; 95% CI: 1.517–13.046), CREBBP (HR = 2.727; 95% confidence interval = 1.163–6.396), and column (HR = 0.544; HR = 0.311–0.952) was significantly associated with changes in disease progression after adjusting for clinical and pathologic factors. In the multiple gene model, only POLE remained a significant predictor of recurrence after adjusting for the same clinical variables. Reverse selection determined recurrence status and extent of resection and mutations ATM (HR = 7.333; 95% confidence interval = 2.318 – 23.195) and column (HR = 0.413; 95% CI = 0.229–0.743) as a predictor of recurrence.
Mutations in ATM and CREBBP have been associated with accelerated meningioma recurrence, and mutations in POLE were protective against recurrence. Each mutation has potential implications for treatment. The impact of these mutations on neoplastic outcome and as potential targets for intervention warrants future study.”
Correspondence to: Jonathan T. e-mail: firstname.lastname@example.org
Key words: Meningioma, Molecular Genome, Pole, ATM, CREBBP
Oncology It is a traditional peer-reviewed, open-access journal that covers the rapidly growing field of cancer research, especially emerging topics not currently covered by other journals. This journal has a special mission: to free oncology from the cost of publishing. It is free for readers and authors.
Learn more about OncologyVisit Oncoscience.us Connect with us on social media:
For media inquiries, Please communicate email@example.com.
Oncology Journal office
6666 East Quaker Str., Suite 1D
Orchard Park, New York 14127
Phone: 1-800-922-0957, option 4
An observational study
human tissue samples
Association between tumor mutations and meningioma recurrence in grade I/II disease
The date the article was published
December 9, 2022
Not giving an opinion: AAAS and EurekAlert! Not responsible for the accuracy of the newsletters sent on EurekAlert! Through contributing organizations or for using any information through the EurekAlert system.